Emergent Bioservices. Makers of a Better World
Emergent Bioservices Capabilties Overview
Emergent Bioservices offers development services, drug substance, and drug product manufacturing for biological products, from clinical through commercialization. Download our overview brochure to learn more about how we can support your next development or manufacturing program.
Facility Spotlight: Comprehensive Fill/finish Solutions for Biologics
Located just 10 minutes from Emergent headquarters, our 70,000 sq. ft. Rockville, MD (USA) facility provides drug product manufacturing for vaccines and therapeutics. We have the capabilities to fill, lyophilize, inspect, label, package, and store vaccine products. Clients collaborating with our drug product team can leverage our groninger® INTEGRA, a high-speed vial filling line. With an integrated SKAN isolator, the INTEGRA is ideal for large-scale clinical and commercial fill/finish projects. Within the facility, we also offer automated visual inspection and packaging and labeling solutions. Learn how Emergent can help advance your next fill/finish manufacturing program.
How to Mitigate Risk for Biologics During Fill/Finish Manufacturing
As more biologics move through research and development, the demand for specialized aseptic fill/finish services has steadily climbed. Aseptic processing with the highest degree of sterility assurance, filling accuracy and quality is critical for high-value, small-batch therapies. Anything less impacts regulatory compliance, project timelines and—most importantly—patient safety. This white paper explores the specialized equipment, expertise, and services needed for efficient biologics fill/finish manufacturing. Download the white paper to learn more.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
